This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Innate Pharma Releases Share Count
Regulatory regulatory filing

Innate Pharma Releases Share Count

Analysis based on 6 articles · First reported Apr 13, 2026 · Last updated Apr 13, 2026

Sentiment
0
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This event has a neutral impact on the markets as it is a routine regulatory disclosure by Innate Pharma. It provides transparency regarding the company's share structure and voting rights, which is important for investors and market participants.

Biotechnology Pharmaceuticals
Event Summary

Innate Pharma, a clinical-stage biotechnology company, released its total number of shares outstanding and voting rights as of April 9, 2026. This disclosure was made in compliance with article L. 233-8 II of the French Code de Commerce and article 223-16 of the France — Autorité des marchés financiers General Regulation. The company reported 93,860,680 total shares outstanding and 94,484,443 theoretical voting rights. Innate Pharma, headquartered in France with a US office, is listed on Euronext Paris and Nasdaq, and also files reports with the United States — United States Securities and Exchange Commission. The company is developing immunotherapies for cancer patients and has collaborations with companies like Sanofi and AstraZeneca.

Entities Involved
stock
Innate Pharma
Innate Pharma released its total number of shares outstanding and voting rights as of April 9, 2026, in compliance with French regulatory requirements.
Importance 100.0 Sentiment 0.0
govactor
France — Autorité des marchés financiers
The France — Autorité des marchés financiers is the French stock-market authority whose regulations Innate Pharma is complying with by releasing its share and voting rights information.
Importance 70.0 Sentiment 0.0
stock
AstraZeneca
AstraZeneca is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations, including the development of monalizumab.
Importance 5.0 Sentiment 0.0
stock
Sanofi
Sanofi is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations.
Importance 5.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
Importance 0.0 Sentiment 0.0
cnt
France
Importance 0.0 Sentiment 0.0
cnt
United States
Importance 0.0 Sentiment 0.0
Relationships
France — Autorité des marchés financiers related ↔ France
AstraZeneca related ↔ United States
Sanofi related ↔ United States
United States — United States Securities and Exchange Commission related ↔ France
United States — United States Securities and Exchange Commission related ↔ United States
France strained allies ↔ United States France remains a core NATO ally of the United States but actively opposes Washington's unilateral military actions, part
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.